Dose-dense sequential
chemotherapy appears to be a promising approach in the management of patients with operable
breast cancer. We evaluated the tolerability of such a novel chemotherapeutic regimen in high-risk patients. From February 1995 until September 1997, 49 women with histologically confirmed
breast cancer and > or =10 involved axillary nodes were treated postoperatively with three cycles of
epirubicin (110 mg/m(2)) followed by three cycles of
paclitaxel (250 mg/m(2) in a 3-hour infusion) followed by three cycles of 'intensified' CMF (
cyclophosphamide 840 mg/m(2),
methotrexate 57 mg/m(2),
fluorouracil 840 mg/m(2); E-T-CMF). All cycles were repeated every 2 weeks with
G-CSF support. Ovarian ablation with monthly
injections of
triptorelin for 1 year was performed in premenopausal patients and
tamoxifen was prescribed for 5 years to all women with positive receptor status after the completion of
chemotherapy. A total of 456 cycles of
chemotherapy were administered, 363 (80%) of them at full dose. Forty-seven (96%) patients received all 9 cycles of
chemotherapy. Relative dose intensity of
epirubicin was 0.98, of
paclitaxel 0.97, of
cyclophosphamide 0.99, of
methotrexate 0.98 and of
fluorouracil 0.99. Grade 3--4 toxicities included
anemia (8%),
leukopenia (8%),
peripheral neuropathy (6%),
neutropenia (4%),
thrombocytopenia (4%),
stomatitis (2%),
diarrhea (2%),
fatigue (2%) and
hypersensitivity reaction (2%).
Febrile neutropenia occurred in 2 patients.
Alopecia was universal. After a median follow-up of 3 years, 11 women (22%) relapsed and 4 (8%) died. The 3-year actuarial disease-free survival rate was 72% and the 3-year overall survival rate 90%. The E-T-
CMF regimen is well tolerated, as adjuvant treatment, in patients with operable
breast cancer with promising activity and deserves further evaluation in phase III studies.